Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation
From General Health to Occupational Exposure Concerns
The legacy of general health and science information has long emphasized broad public awareness of disease prevention and therapeutic options. This foundational knowledge has guided both clinical practice and occupational health frameworks, particularly in contexts where environmental or chemical exposures are routine. As industrial processes evolve, the focus naturally shifts from general health promotion to specific risk factors encountered in workplace settings. One such area of emerging concern involves the intersection of pharmaceutical agents and occupational exposure. Specifically, the use of immunotherapeutic drugs like Avelumab, approved for certain cancers, raises questions about potential risks for workers who may handle or be exposed to these substances during manufacturing. The transition from general health education to occupational exposure concern requires careful consideration of how such agents might influence disease risk, including Merkel cell carcinoma. While the legacy context provides a baseline for understanding cancer biology and prevention, the occupational lens demands scrutiny of exposure pathways, dose-response relationships, and workplace safety protocols. This pivot underscores the need for targeted research into whether Avelumab exposure in production environments correlates with altered risk profiles, without prematurely attributing mechanistic causation.
Avelumab: Mechanism and Therapeutic Role in Merkel Cell Carcinoma
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Merkel Cell Carcinoma: Etiology and Risk Factors
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/;https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit for advanced MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/;https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/35877101/;https://pubmed.ncbi.nlm.nih.gov/34445385/).
Evidence on Avelumab and MCC Risk: Therapeutic vs. Causal Link
The relationship between avelumab and Merkel cell carcinoma is primarily therapeutic, as avelumab is used to treat metastatic MCC. However, the risk narrative involves the potential for avelumab to be ineffective or to cause adverse effects in patients with MCC. For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). Studies have investigated the use of combined ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. In a retrospective study at three different sites in Germany, clinical and molecular data of five patients with metastatic MCC refractory to avelumab and later treated with combined ipilimumab/nivolumab were collected and evaluated; three out of five patients responded to the combination therapy according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG also examined ipilimumab plus nivolumab in avelumab-refractory MCC, noting that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC confirmed that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Causation Considerations and Patient Risk Context
Regarding causation-related considerations for affected patients, the timeline between avelumab exposure and documented harm is not directly addressed in the provided evidence. The evidence focuses on avelumab as a treatment for MCC rather than as a cause of MCC. The risk for patients involves the possibility of non-response or progression while on avelumab therapy, as well as immune-related adverse events. The adequacy of warnings regarding avelumab and Merkel cell carcinoma is not explicitly discussed in the evidence snippets, but the approval and clinical trial data indicate that avelumab is indicated for metastatic MCC, and its use is associated with both benefits and risks, including the potential for lack of response or adverse events. In summary, avelumab is an approved treatment for metastatic Merkel cell carcinoma, with evidence of efficacy in approximately one-third of patients in a key clinical trial. However, about half of patients may not respond or may experience progression, and alternative treatments such as ipilimumab plus nivolumab have been studied in avelumab-refractory cases. The evidence does not support a causal link between avelumab and the development of MCC; rather, avelumab is used to treat the disease.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is avelumab and how does it work?
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for the treatment of metastatic Merkel cell carcinoma.
Is there a causal link between avelumab and Merkel cell carcinoma?
No, the evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is used as a treatment for the disease, not as a cause. The primary risks associated with avelumab are lack of response or progression while on therapy, as well as immune-related adverse events.
What are the treatment options for patients who do not respond to avelumab?
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.